Bristol Myers Squibb's Growth Portfolio Just Hit $7.7 Billion. Is This Cheap Pharma Stock a No-Brainer Buy?
Bristol Myers Squibb's growth portfolio generated $7.7 billion in quarterly revenue with 12% year-over-year growth, representing nearly 60% of drug revenues. The stock offers an attractive 4.3% dividend yield and trades at a 13x P/E ratio, below the pharma industry average of 28x. However, the company faces a significant headwind: its legacy drug Eliquis, which generates $4.7 billion annually, faces generic competition starting in 2028. While the successful growth portfolio demonstrates strong drug development execution, investors remain cautious about the upcoming patent expiration.



